1. Home
  2. NKX vs MLYS Comparison

NKX vs MLYS Comparison

Compare NKX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California AMT-Free Quality Municipal Income Fund

NKX

Nuveen California AMT-Free Quality Municipal Income Fund

HOLD

Current Price

$12.54

Market Cap

645.5M

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$37.91

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKX
MLYS
Founded
2002
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
645.5M
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
NKX
MLYS
Price
$12.54
$37.91
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$47.33
AVG Volume (30 Days)
109.3K
1.6M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
4.37%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.78
$8.24
52 Week High
$12.00
$47.65

Technical Indicators

Market Signals
Indicator
NKX
MLYS
Relative Strength Index (RSI) 35.61 43.48
Support Level $12.43 $36.01
Resistance Level $12.80 $39.15
Average True Range (ATR) 0.06 1.81
MACD -0.03 -0.16
Stochastic Oscillator 24.32 31.53

Price Performance

Historical Comparison
NKX
MLYS

About NKX Nuveen California AMT-Free Quality Municipal Income Fund

Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: